Cerus (CERS) ROCE % : -2.88% (As of Sep. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Cerus ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cerus's annualized ROCE % for the quarter that ended in Sep. 2024 was -2.88%.

Cerus ROCE % Historical Data

The historical data trend for Cerus's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus ROCE % Chart

Cerus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-57.45

-40.36

-30.67

-28.08

-25.02

Cerus Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-15.53	2.85	-22.53	-10.63	-2.88

Cerus ROCE % Calculation

Cerus's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-28.936	/	( ( (218.092 - 117.058)	+	(197.748 - 67.521) )	/ 2 )
	=	-28.936	/	( (101.034	+	130.227)	/ 2 )
	=	-28.936	/	115.6305
	=	-25.02 %

Cerus's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-3.844	/	( ( (185.496 - 53.884)	+	(189.539 - 54.345) )	/ 2 )
	=	-3.844	/	( ( 131.612	+	135.194 )	/ 2 )
	=	-3.844	/	133.403
	=	-2.88 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Cerus (NAS:CERS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cerus ROCE % Related Terms

Thank you for viewing the detailed overview of Cerus's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (NAS:CERS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CU2:Germany CU2:Germany

Address

1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520

Website

https://www.cerus.com

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Executives

Kevin Dennis Green	officer: Chief Accounting Officer	C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Chrystal Menard	officer: Chief Legal Officer	C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Richard J Benjamin	officer: Chief Medical Officer	15 WHITE PINE ROAD, NEWTON MA 02464
Hua Shan	director	C/O CERUS CORPORATION, 1220 CONCORD AVE., STE. 600, CONCORD CA 94520
Jami K Nachtsheim	director
Swisher Daniel N Jr	director	C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Frank Witney	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
William Mariner Greenman	officer: President, Cerus Europe	C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Laurence M Corash	director	C/O CERUS CORP, 2411 STENWELL DRIVE, CONCORD CA 94520
Vivek K Jayaraman	officer: Chief Commercial Officer	3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Carol Moore	officer: SR. V.P. Regulatory, Clinical	C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Eric Bjerkholt	director	132 PURDURE AVENUE, KENGSINGTON CA 94708
Ann Lucena	director	C/O CERUS CORPORATION, 1220 CONCORD AVE. SUITE 600, CONCORD CA 94520
Gail Schulze	director	3451 WELLS ROAD, MALVERN PA 19355
Timothy B Anderson	director	C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015